piezo Therapeutics Unveils Positive Preclinical Data Demonstrating LNP-Free mRNA Vaccine Delivery
Piezo Therapeutics, a spinout from Georgia Tech, has announced positive preclinical data for its formulation-free delivery platform, piezopen. This platform aims to enhance gene expression and immunogenicity in naked mRNA vaccines, making them comparable to benchmark lipid nanoparticle (LNP) formulations.
the company is focused on advancing next-generation nucleic acid vaccines and therapeutics. By integrating innovations in drug delivery and genetic medicine, Piezo Therapeutics collaborates with global pharma and biotech companies to prevent and treat debilitating diseases.Key Points:
- Piezo Therapeutics has raised initial financing in 2023, backed by Good Ventures.
- The companyS platform, Piezopen, delivers mRNA vaccines without the need for LNP formulations.
- Preclinical data demonstrates that Piezopen can achieve gene expression and immunogenicity similar to LNP-based vaccines.
For more information, visit www.piezotx.com.
Media Contact:
Gaurav Byagathvalli
Piezo Therapeutics
Phone: 1 404-997-3263
Email: [protected email]
Website: www.piezotx.com
Piezo Therapeutics, a spinout from Georgia Tech, has announced positive preclinical data for its formulation-free delivery platform, piezopen. This platform aims to enhance gene expression and immunogenicity in naked mRNA vaccines, making them comparable to benchmark lipid nanoparticle (LNP) formulations. The company is focused on advancing next-generation nucleic acid vaccines and therapeutics. By integrating innovations in drug delivery and genetic medicine, Piezo Therapeutics collaborates with global pharma and biotech companies to prevent and treat debilitating diseases.
Interview with Dr. Lisa Krantz, Chief Scientific Officer of Piezo Therapeutics
Table of Contents
Introduction to Piezo Therapeutics and Piezopen
Senior Editor of world-today-news.com: Could you provide an overview of Piezo therapeutics and explain what the company is doing to revolutionize mRNA vaccine delivery?
Dr. Lisa Krantz: Piezo Therapeutics is dedicated to enhancing the efficacy and availability of nucleic acid therapeutics, especially vaccines. Our signature platform, piezopen, is designed to deliver mRNA vaccines without the need for lipid nanoparticles (LNPs). By eliminating the requirement for LNPs, we aim to streamline production, reduce costs, and enhance the distribution of life-saving vaccines.
Preclinical Data and Achievements
Editor: recent reports indicate positive preclinical data for piezopen. Could you highlight some of these achievements and their meaning?
dr. Krantz: Indeed, our preclinical data shows that piezopen can achieve gene expression and immunogenicity comparable to LNP-based vaccines. This is a significant milestone as it demonstrates that our formulation-free delivery system can be just as effective as customary LNP-based approaches. This achievement paves the way for more efficient and scalable vaccine production.
Funding and Collaborations
Editor: Piezo Therapeutics recently received initial financing. How is this funding going to help in the growth and deployment of your technologies?
Dr. Krantz: The funding received from Good Ventures is crucial for advancing our preclinical studies into clinical trials. It will also help us in scaling our production capabilities and partnering with more global pharma and biotech companies. These collaborations aim to broaden the application of our technology, not just for vaccines but also for various therapeutic interventions.
Futures
Editor: What are the key goals for Piezo Therapeutics over the next few years?
Dr. Krantz: Over the next few years, we aim to translate our promising preclinical findings into triumphant clinical trials. Additionally, we are focusing on expanding our technology’s applications beyond vaccines to include gene therapies and other nucleic acid-based therapies.Our goal is to make these therapies more accessible and effective globally.
Conclusion
Editor: Any final thoughts on the impact of Piezo Therapeutics’ work in the field of genetic medicine?
Dr.Krantz: I believe our work at Piezo Therapeutics holds great promise for the future of genetic medicine. By improving the delivery mechanisms for RNA vaccines and therapies, we can make significant advances in preventing diseases and improving the quality of life for patients worldwide. This is an exciting time for our field, and we’re thrilled to be at the forefront of this innovation.
Media Contact
For more information, visit www.piezotx.com.
Gaurav Byagathvalli
Piezo Therapeutics
Phone: 1 404-997-3263
Email: [protected email]
